Juan Carlos Ferrero
World No. 1 Tennis Champion & French Open Winner | Elite Coach of Carlos Alcaraz | Founder, Equelite Sport Academy
2019 Nobel Laureate in Physiology or Medicine | Sidney Farber Professor of Medicine, Harvard & Dana-Farber | HHMI Investigator
One of medicine's most transformative minds, William G. Kaelin Jr. won the 2019 Nobel Prize in Physiology or Medicine for cracking the code of how cells sense oxygen — work that gave rise to a new generation of cancer therapies. Sidney Farber Professor at Harvard and a Howard Hughes Medical Institute Investigator, his research turned fundamental biology into approved treatments for kidney cancer. On stage, he makes the science of discovery urgently relevant.
Want to book William G. Kaelin Jr as a speaker for your event? Please provide the info below and we’ll get in touch within 24h:
William G. Kaelin Jr. is one of the most consequential figures in modern cancer biology — a physician-scientist whose work on oxygen sensing fundamentally altered our understanding of how cells survive, adapt, and, when things go wrong, turn malignant. He is the Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, a Senior Physician-Scientist at Brigham and Women’s Hospital, and a Howard Hughes Medical Institute Investigator — positions he has held since the late 1990s and early 2000s.
Nobel Prize speaker William G. Kaelin Jr. is best known for deciphering the molecular mechanism by which cells detect and respond to changes in oxygen availability — a discovery with sweeping implications for cancer, anemia, cardiovascular disease, and macular degeneration. Working on the von Hippel-Lindau (VHL) tumor suppressor gene and its protein product, Kaelin demonstrated that the VHL protein acts as a critical regulator of hypoxia-inducible factors (HIFs), the master switches that control how genes respond to low oxygen. When VHL is mutated or absent — as in clear-cell kidney cancer — HIFs run unchecked, driving the growth of abnormal blood vessels and fueling tumor progression.
This work, conducted in parallel with the independent research of Sir Peter J. Ratcliffe and Gregg L. Semenza, directly enabled a new class of targeted cancer therapies: VEGF inhibitors and, eventually, the first HIF2 inhibitor approved for the treatment of kidney cancer. The translational impact of Kaelin’s basic science research is rare in both speed and scope.
In 2019, Kaelin, Ratcliffe, and Semenza were jointly awarded the Nobel Prize in Physiology or Medicine for their discoveries of how cells sense and adapt to oxygen availability — a recognition of work that moved from basic biochemistry to life-saving treatments within a generation. His broader contributions have earned him the Albert Lasker Basic Medical Research Award, the Canada Gairdner International Award, election to the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences, among many other honors. In 2024, he was elected a Member of the American Philosophical Society.
As a Nobel Prize speaker, William G. Kaelin Jr. brings an extraordinary perspective to questions that matter deeply to scientific, academic, corporate, and philanthropic audiences: how curiosity-driven science produces breakthroughs that applied research alone cannot generate, why supporting basic research is essential to long-term medical and economic progress, and how physician-scientists navigate the intersection of clinical insight and laboratory discovery. Audiences leave not only inspired by the arc of his career but equipped with a clearer understanding of how transformative science actually happens — and what it demands of institutions willing to support it.
This keynote traces the scientific journey from a fundamental biological question — how do cells detect and adapt to oxygen levels? — to a Nobel Prize-winning answer and a new class of cancer drugs. Kaelin recounts how studying the VHL tumor suppressor gene revealed a master regulatory system governing the body's hypoxic response, and how that insight ultimately drove the development of treatments for kidney cancer and anemia. A compelling demonstration of how curiosity-driven science produces results that targeted research alone never could.
Drawing on his own career and broader trends in research funding, Kaelin makes a rigorous and personal case for sustaining investment in fundamental science. He challenges the prevailing bias toward applied research and argues that the most transformative medical advances — including his own Nobel-recognized work — emerged not from structured programs but from scientists following unexpected leads. Essential for research institutions, philanthropic foundations, and science policy audiences.
An authoritative exploration of how mutations in tumor suppressor genes drive malignancy, and what that means for the next generation of cancer therapies. Kaelin explains the biological logic of VHL, pRB, and related proteins, how their loss creates specific vulnerabilities in cancer cells, and why synthetic lethality strategies hold promise for targeting cancers that have long resisted treatment. Pitched for scientific and biomedical audiences seeking depth alongside inspiration.
A personal and candid account of Kaelin's path from self-described late-bloomer to Nobel Laureate — including early failures, mentors who made the difference, and the moments of unexpected discovery that defined his career. He draws on the analogy between fishing and science: the interplay of technical skill, intuition, and luck that governs both pursuits. Ideal for students, early-career researchers, and any audience that values honest reflections on long-term ambition and resilience.
| Basic Data Protection Information | |
|---|---|
| Data controller | AURUM SPEAKERS BUREAU S.L. |
| Address | Parc Audiovisual de Catalunya 1, Oficina S11, 08225 Terrassa, Spain |
| Purposes | We will use your data to respond to your requests and deliver our services to you. |
| Marketing | We will only send you marketing correspondence if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Lawful basis | We will only process your data if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Recipients | Generally, only our members of staff who have been duly authorised may access the data that you have provided. |
| Your Rights | You have the right to know what information we hold about you, to rectify it and to erase it, as explained in the additional information available on our website. |
| Additional Information | For more information, please see “PRIVACY POLICY” on our website. |